In recent years of research in immunology, the understanding
of innate immunity has deepened, and the concept of innate immunity has been
proposed even in the field of acquired immunity. The conventional
immunosuppressive treatments mainly act via regulation of acquired immunity.
However, the involvement of innate immunity was confirmed for
hydroxychloroquine (HCQ), which has been confirmed to be effective in the
treatment of cutaneous lupus erythematosus (CLE). Approximately 1.5 years prior
to this trial, HCQ was officially approved for use in Japan by the Japanese
Ministry of Health, Labor and Welfare for the treatment of CLE and SLE in
September 2015. This review introduces the mechanism underlying the development
of CLE from the viewpoint of autoantibodies, cytokines, and innate immunity.
Furthermore, the mechanism of action of HCQ is introduced and discussed.
Author(s) Details:
Fukumi Furukawa,
Department of Forensic Medicine, Wakayama Medical University, 811-1
Kimiidera, 641-8509 Wakayama, Japan.
Please see the link here: https://stm.bookpi.org/ANUMS-V6/article/view/13363
No comments:
Post a Comment